Plain language summary of the TALAPRO-2 study: Talazoparib plus enzalutamide versus placebo plus enzalutamide for advanced prostate cancer with specific DNA repair gene alterations

This Plain Language Summary of Publication article (PLSP) from Future Oncology, tested the combination of talazoparib and enzalutamide as a first treatment for adults with metastatic castration-resistant prostate cancer (mCRPC). This part of the study focused on patients whose tumors had specific DNA repair gene changes, which might make cancer cells more responsive to the combination treatment. Researchers compared talazoparib plus enzalutamide with a placebo plus enzalutamide to evaluate its effectiveness.

Visit the site using this link to read the article.

This PLSP is based on an article called ‘First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial’ and was published in the Nature Medicine.

Visit Nature using the link to read the original article.

• clinical trials
• Genetics
• metastasis
• novel therapy
• Urologic/Prostate